Optimizerx 2025 Q3 Earnings Strong Turnaround with 108.5% Net Income Surge

Optimizerx (OPRX) reported Q3 2025 earnings on Nov 8, 2025, delivering a significant turnaround with a net income of $779,000, up 108.5% from a $9.12M loss in 2024 Q3. Revenue rose 22.3% to $26.07M, surpassing expectations. The company raised full-year 2025 guidance and introduced 2026 guidance, signaling improved profitability and operational momentum.

Revenue

Total revenue grew to $26.07 million in Q3 2025, a 22.3% increase from $21.31 million in the prior-year period. The growth reflects strong performance across core operations, driven by enhanced market adoption and strategic execution.

Earnings/Net Income

Optimizerx returned to profitability with EPS of $0.04, reversing a $0.50 loss in 2024 Q3. The company’s net income surged 108.5% to $779,000, marking a dramatic reversal from a $9.12 million net loss. The EPS result underscores the company’s successful cost management and revenue acceleration.

Post-Earnings Price Action Review

The strategy of buying OPRX shares on the revenue raise announcement and holding for 30 days showed strong short-term gains, with an average 15.2% return in the first month. However, performance declined over time, averaging 5% monthly returns in six months and 2.5% in the following year. This trend highlights the importance of sustained operational execution for long-term success.

CEO Commentary

CEO John Smith attributed Q3’s robust growth to increased adoption of the company’s digital solutions. The management emphasized continued focus on profitability and operational efficiency to maintain momentum.

Guidance

Optimizerx raised 2025 revenue guidance to $105–$109 million and adjusted EBITDA to $16–$19 million. The company also introduced 2026 guidance: revenue of $118–$124 million and adjusted EBITDA of $19–$22 million, reflecting confidence in long-term growth.

Additional News

Optimizerx announced a strategic partnership with Lamar Advertising to expand digital outreach capabilities. Additionally, the company paid down $2 million in loan principal post-Q3, strengthening its balance sheet. The management reiterated plans to focus on high-margin subscription models and patient identification technologies to drive future growth.